Skip to content

Mechanism and Clinical research of Zhenganxifeng dispensing granule decoction for treatment of hypertension with Yin Deficiency and Yang Hyperactivity Syndrome based on network pharmacology

Mechanism and Clinical research of Zhenganxifeng dispensing granule decoction for treatment of hypertension with Yin Deficiency and Yang Hyperactivity Syndrome based on network pharmacology

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003146
Enrollment
Unknown
Registered
2020-03-23
Start date
2020-03-31
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Sponsors

Affiliated Hospital of Shandong University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. it conforms to the diagnostic criteria of essential hypertension in western medicine and the diagnostic criteria of Yin deficiency and Yang hyperactivity syndrome of vertigo; Hypertension was grade 1, and was diagnosed as essential hypertension (grade 1) with Yin deficiency and Yang hyperactivity after standard lifestyle intervention; 2. In the past 2 weeks, blood pressure was stable, without the treatment of traditional Chinese medicine or proprietary Chinese medicine, after the treatment of western medicine, blood pressure was still in hypertension level 1 patients. 3. aged between 18 and 75 years old; 4. Volunteer to participate in the experiment and sign the informed consent, and cooperate with various investigations and tests.

Exclusion criteria

Exclusion criteria: 1. secondary hypertension, refractory hypertension, malignant hypertension, acute and subacute hypertension, white coat hypertension and unstable blood pressure; 2. pregnant and lactating women, women of child-bearing age do not agree to use contraceptive measures during the experiment; 3. Have mental illness, can't cooperate very well; 4. confirmed to have serious heart disease, severe neurosis and heart, liver, kidney insufficiency; 5. There are severe endocrine, hematopoietic system, liver, kidney and other primary diseases, malignant tumors, mental patients; 6. Uncorrected hyperthyroidism, hypothyroidism; Patients with nephrotic syndrome, diabetes mellitus and acute hepatobiliary disease; 7. people who have suffered from serious cerebrovascular accidents, heart diseases, severe trauma, major surgery and other primary diseases with unstable general conditions and poor prognosis within 6 months; 8. Complicated with other diseases and is receiving medication treatment.

Design outcomes

Secondary

MeasureTime frame
Routine urine;Total cholesterol;Routine blood;ECG;Liver function;triglycerides;Routine stool;HDL-C;Blood sugar;LDL-C;Renal function;

Primary

MeasureTime frame
Ventricular brachial artery blood pressure;Quality of life score;24-hour dynamic blood pressure monitoring;symptom score of TCM;ADRA1A \ADRA1B\NOS3\MAOB;

Countries

China

Contacts

Public ContactLi Yunlun

Affiliated Hospital of Shandong University of TCM

li.yunlun@163.com+86 13869102760

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026